Kintor shares plunge after hair-loss drug flops in clinical trials
The company’s drug has failed to show a significant hair-boosting effect in Phase III trials, dashing investors’ hopes for a ground-breaking treatment for baldness Key Takeaways: The disappointing test results…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Yonghe Medical’s share repurchase gets results, but can’t hide a receding profit line
2279.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
FAST NEWS: Nomura takes up Kintor Pharma stake
9939.HK
- HighTide Therapeutics places big IPO bet on “affluenza” drug
